Clinicopathological analysis of oral diffuse large B‐cell lymphoma, NOS: a systematic review

Abstract

Background

Diffuse large B‐cell lymphoma, NOS (DLBCL NOS) is the commonest extranodal non‐Hodgkin lymphoma diagnosed in the oral and maxillofacial region. However, few studies are currently available and its prognostic determinants still remain undefined.

Purpose

To analyse the available data on oral DLBCL NOS and to describe its clinicopathological features, identifying potential prognostic factors.

Methods

An electronic systematic search was performed using multiple databases with a specific search strategy in April 2018. All reports describing DLBCL NOS involving the oral cavity and jaw bones with sufficient clinicopathological information were assessed.

Results

Sixty‐three publications were included in the study, comprising 122 cases. Oral DLBCL NOS was found predominantly in elderly males (61.5%), and most often presented as an asymptomatic swelling of the gingiva. Patients commonly were HIV‐negative (36.1%), with few reports describing EBV‐positive cases (4 cases/3.3%). Only 8 cases presented B‐symptoms and most cases were classified as stage I or II (48.4%). CHOP therapy was the main treatment option (24.5%) and the overall 5‐year survival rate achieved 83%. Males and advanced Ann‐Arbor stage patients presented significantly lower survival rates in the univariate analysis, but no significance was found in the multivariate model.

Conclusion

Oral DLBCL NOS is an aggressive malignancy, but with a high survival rate.

This article is protected by copyright. All rights reserved.

from OroFacial via a.sfakia on Inoreader https://ift.tt/2PmY6Mo